Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Lexicon Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

THE WOODLANDS, TEXAS, DEC. 10, 2025 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC.(NASDAQ: LXRX) TODAY ANNOUNCED THE PUBLICATION OF PRECLINICAL DATA VALIDATING ACYL-COA SYNTHETASE 5 (ACSL5) AS A TARGET FOR OBESITY AND CHRONIC WEIGHT MANAGEMENT. THE PAPER, TITLED ACYL-COA SYNTHETASE 5 KNOCKOUT AND INHIBITORS PROTECT AGAINST DIET-INDUCED OBESITY IN MICE BY ACTIVATING THE ILEAL BRAKE, WAS PUBLISHED ONLINE IN THE JOURNAL OF THE ENDOCRINE SOCIETY.

LEXICON PHARMACEUTICALS ANNOUNCES PUBLICATION OF PRECLINICAL DATA IN THE JOURNAL OF THE ENDOCRINE SOCIETY ON ACYL-COA SYNTHETASE 5 (ACSL5) REINFORCING THE SCIENTIFIC RATIONALE FOR LX9851

THE WOODLANDS, TEXAS, DEC. 05, 2025 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC. (NASDAQ: LXRX) ANNOUNCED CLINICAL DATA ON ADIPOSE TISSUE DISTRIBUTION IN NON-DIABETIC PATIENTS TREATED WITH SOTAGLIFLOZIN WILL BE PRESENTED AT THE 22ND GLOBAL CARDIO VASCULAR CLINICAL TRIALISTS FORUM (CVCT 2025). THE CONFERENCE IS BEING HELD DECEMBER 8-10, 2025, AT THE MAYFLOWER HOTEL IN WASHINGTON, D.C.

CLINICAL DATAON EFFECT OF SOTAGLIFLOZIN ON ADIPOSE DISTRIBUTION IN NON-DIABETIC PATIENTSWILL BEPRESENTEDAT THE 2025 CARDIO VASCULAR CLINICAL TRIALISTS FORUM

THE WOODLANDS, TEXAS, NOV. 25, 2025 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC. (NASDAQ: LXRX) TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE ON WEDNESDAY, DECEMBER 3 AT 9:00 A.M. ET AND AT THE 8TH ANNUAL EVERCORE HEALTHCARE CONFERENCE ON THURSDAY, DECEMBER 4 AT 9:10 A.M. ET.

LEXICON PHARMACEUTICALS TO PARTICIPATE IN TWO UPCOMING DECEMBER INVESTOR CONFERENCES

THE WOODLANDS, TEXAS, NOV. 11, 2025 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC. (NASDAQ: LXRX) TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE JEFFERIES 2025 LONDON HEALTHCARE CONFERENCE ON TUESDAY, NOVEMBER 18 AT 5:00 P.M. GMT (12:00 P.M.

LEXICON PHARMACEUTICALS TO PARTICIPATE AT THE JEFFERIES 2025 LONDON HEALTHCARE CONFERENCE

THE WOODLANDS, TEXAS, NOV. 08, 2025 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC. (NASDAQ: LXRX) TODAY ANNOUNCED THAT NEW SOTAGLIFLOZIN CLINICAL DATA WAS PRESENTED AT THE AHA ANNUAL SCIENTIFIC SESSIONS 2025. THE DATA HIGHLIGHTED BENEFITS OBSERVED FROM SOTAGLIFLOZIN TREATMENT IN HEART FAILURE PATIENTS WITH PRESERVED EJECTION FRACTION (HFPEF), AND WITHOUT DIABETES, ACROSS A RANGE OF MEASURES, INCLUDING CARDIAC STRUCTURE AND FUNCTION, QUALITY OF LIFE AND FUNCTIONAL CAPACITY.

CLINICAL DATA DEMONSTRATING EFFICACY OF SOTAGLIFLOZIN IN PRESERVED EJECTION FRACTION HEART FAILURE (HFPEF) WITHOUT DIABETES PRESENTED AT AMERICAN HEART ASSOCIATION (AHA) ANNUAL SCIENTIFIC SESSIONS 2025

FDA END-OF-PHASE 2 MEETING FOR PILAVAPADIN IN DPNP TO BE HELD BY YEAR-END ALL IND-ENABLING STUDIES OF LX9851 FOR OBESITY COMPLETED AND SUBMITTED TO LICENSEE NOVO NORDISK SITE INITIATION FOR SONATA-HCM PHASE 3 STUDY OF SOTAGLIFLOZIN IN BOTH OBSTRUCTIVE AND NON-OBSTRUCTIVE HCM COMPLETED; ENROLLMENT COMPLETION ON TARGET FOR 2026 ADDITIONAL DATA IN SUPPORT OF POTENTIAL RESUBMISSION OF ZYNQUISTA FOR TYPE 1 DIABETES SUBMITTED TO FDA CONFERENCE CALL AND WEBCAST AT 8:30 AM ET  THE WOODLANDS, TEXAS, NOV. 06, 2025 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC. (NASDAQ: LXRX), TODAY REPORTED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2025, AND PROVIDED AN UPDATE ON KEY CORPORATE MILESTONES AND ACCOMPLISHMENTS. LEXICON USHERED IN 2025 WITH AN AMBITIOUS SLATE OF OBJECTIVES EMBRACING AND DRIVING OUR RENEWED R&D FOCUS, SAID MIKE EXTON, PH.D.

LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES R&D UPDATES

THE WOODLANDS, TEXAS, NOV. 04, 2025 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC.  (NASDAQ: LXRX) TODAY ANNOUNCED THAT DATA FROM THREE STUDIES OF SOTAGLIFLOZIN WILL BE PRESENTED DURING UPCOMING MEDICAL MEETINGS. TWO STUDIES WILL BE PRESENTED AT THE AMERICAN HEART ASSOCIATION'S (AHA) SCIENTIFIC SESSIONS 2025, BEING HELD NOVEMBER 7-10 AT THE ERNEST N.

DATA DEMONSTRATING UNIQUE BENEFITS OF SOTAGLIFLOZIN IN DIVERSE PATIENT POPULATIONS WILL BE PRESENTED AT THE HYPERTROPHIC CARDIOMYOPATHY SOCIETY AND AMERICAN HEART ASSOCIATION'S SESSIONS 2025 IN NEW ORLEANS

THE WOODLANDS, TEXAS, OCT. 30, 2025 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC. (NASDAQ: LXRX) TODAY ANNOUNCED THE COMPANY WILL RELEASE ITS THIRD QUARTER 2025 FINANCIAL RESULTS ON THURSDAY, NOVEMBER 6, 2025, PRIOR TO MARKET OPEN. MANAGEMENT WILL CONDUCT A CONFERENCE CALL AND LIVE WEBCAST AT 8:30 A.M. ET (7:30 A.M. CT) THAT DAY TO DISCUSS THE FINANCIAL RESULTS AND TO PROVIDE A BUSINESS UPDATE.

LEXICON PHARMACEUTICALS TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS ON NOVEMBER 6, 2025

 RESULTS SUPPORT ADVANCEMENT OF 10 MG DOSE INTO PHASE 3 DEVELOPMENT   END-OF-PHASE 2 MEETING REQUEST ACCEPTED BY U.S. FDA; PARTNERSHIP DISCUSSIONS PROGRESSING  THE WOODLANDS, TEXAS, OCT. 14, 2025 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC. (NASDAQ: LXRX) TODAY ANNOUNCED THE COMPANY PRESENTED ADDITIONAL CLINICAL DATA AND PROGRAM UPDATES FROM ITS PHASE 2 PILAVAPADIN PROGRAM AT THE 19TH ANNUAL PAIN THERAPEUTICS SUMMIT. THESE DATA FOLLOW THE TOPLINE RESULTSFROM THE PHASE 2B PROGRESS STUDY OF PILAVAPADIN IN DIABETIC PERIPHERAL NEUROPATHIC PAIN (DPNP) ANNOUNCED IN MARCH OF 2025, WHICH IDENTIFIED 10 MG ONCE DAILY AS THE MOST CLINICALLY MEANINGFUL AND APPROPRIATE DOSE TO ADVANCE INTO PHASE 3 DEVELOPMENT.

LEXICON PHARMACEUTICALS PRESENTS ADDITIONAL PILAVAPADIN DATA IN DIABETIC PERIPHERAL NEUROPATHIC PAIN AT 19TH ANNUAL PAIN THERAPEUTICS SUMMIT

DIVERSE GROUP OF STAKEHOLDERS ALIGNED AROUND THE IMPORTANCE OF ELEVATING PUBLIC AWARENESS OF NEED FOR NEW TREATMENTS FOR CHRONIC PAIN AND THE NEED TO EXPAND THE ALTERNATIVES TO PAIN ACT DIVERSE GROUP OF STAKEHOLDERS ALIGNED AROUND THE IMPORTANCE OF ELEVATING PUBLIC AWARENESS OF NEED FOR NEW TREATMENTS FOR CHRONIC PAIN AND THE NEED TO EXPAND THE ALTERNATIVES TO PAIN ACT

Lexicon Pharmaceuticals, Inc.

LXRX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Lexicon Pharmaceuticals, Inc.

LXRX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

LXRX